Compare Iron Mountain Inc (IRM) vs Pfizer Inc (PFE) Price & Performance

Iron Mountain (IRM) trades at $112.97, down 3.03% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust revenue growth from $5.1B in 2022 to $6.9B in 2025, though net margins have compressed. Recent developments highlight expansion in data centers and digital solutions, with a 300MW pipeline target. Analyst consensus remains bullish with a $142.75 price target, representing 26% upside potential from current levels.

IRM presents a compelling growth story in data center expansion and digital transformation, but faces significant debt burden with 79% debt-to-asset ratio. While institutional ownership is growing and earnings consistently exceed expectations, high valuation multiples and declining profit margins warrant caution. The stock's near-term performance will depend on successful execution of digital initiatives and debt management.

Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.

Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.